JP7512311B2 - Drug administration device - Google Patents

Description

The present invention relates to a drug administration device in which the device body is attached and left on the body surface of a living body.

A drug administration device is a medical instrument that administers a desired dose of drug to a living body at an appropriate time. For example, the system (drug administration device) disclosed in JP2013-500793A comprises a needle device (needle portion) that is inserted into the body from the surface of the body and left there, a delivery device (device body) that stores the drug, and an injection path (tube) that can circulate the drug from the device body to the needle portion.

The drug administration device disclosed in JP2013-500793A has a base (sealing body) for fixing the device body to the body surface. A backing (peelable covering layer) is attached to the bottom surface of this sealing body to protect the adhesive surface until the drug administration device is used.

When placing a drug administration device of this type, the needle is placed, then the tube connected to the needle is connected to the device body, and the device body is attached (placed) in a position near the needle. However, when connecting the end of the tube to the device body and placing the device body, it is easy for the device body to be placed in a position farther than the length of the tube, or for the needle to be pulled when peeling off the backing from the seal of the device body. In other words, conventional drug administration devices have the problem that it is difficult for the user to stably place the device body in accordance with the placement position of the needle and the length of the tube.

The present invention aims to provide a drug administration device that can effectively place the device body on the surface of a living body with a simple configuration, even in a drug administration device in which the needle portion and the device body are connected by a tube as described above.

In order to achieve the above-mentioned object, one aspect of the present invention is a drug administration device comprising a needle portion that is inserted and left in place in a living body, a device main body that is provided separately from the needle portion and capable of delivering a drug from its tip portion, and a tube that allows the drug to flow between the needle portion and the tip portion of the device main body, wherein the device main body comprises a seal body having an adhesive surface that is attached to the body surface of the living body, and a mount that covers the adhesive surface so that it can be exposed before use, the mount including a first mount that covers the tip side of the seal body and a second mount that covers at least the base end side of the seal body, the second mount having a covering portion that covers the adhesive surface, and an operating portion that is connected to the tip of the covering portion and folds back from the tip of the covering portion to extend beyond the base end of the device main body.

The above-mentioned drug administration device can be configured so that the needle portion and the device body are connected by a tube, and the device body can be placed well on the surface of the living body with a simple configuration.

1 is a perspective view showing an overall configuration of a medicine injection device according to an embodiment of the present invention; FIG. 2 is a side cross-sectional view of the drug administration device of FIG. 1; FIG. 2 is a perspective view of the device body as seen from the side that is attached to the body surface to show the body-side seal body and the body-side mount. 1 is a flowchart showing a method for placing the drug administration device. 11 is an explanatory diagram showing a connecting operation between connectors of a medicine injection device. FIG. 11A to 11C are explanatory diagrams showing the peeling operation of the first backing sheet. 11A and 11B are explanatory diagrams showing the peeling operation of the second backing sheet. FIG. 13 is a perspective view showing a main body seal body and a main body mount of a medicine injection device according to a modified example.

A preferred embodiment of the present invention will now be described in detail with reference to the accompanying drawings.

As shown in Figure 1, a drug administration device 10 according to one embodiment of the present invention is configured to be placed on the body surface, such as the abdomen, of a patient (living body) and to automatically administer a drug into the body. For example, the drug administration device 10 is used when administering a drug to a patient a predetermined time after a medical procedure has been performed on the patient, or when administering a drug gradually over time. The drug administered by the drug administration device 10 is not particularly limited, but examples include liquid pharmaceuticals such as antibody drugs, anticancer drugs, chemotherapy drugs, anesthetics, antibiotics, insulin, blood products, and nutrients.

The drug administration device 10 comprises a needle portion 20, a device body 30 capable of supplying a drug, and a tube 40 capable of circulating the drug between the needle portion 20 and the device body 30. In other words, the drug administration device 10 separates the device body 30 from the needle portion 20, allowing the needle portion 20 to be handled independently. This allows the drug administration device 10 to easily and accurately position the needle portion 20 at a desired position on the body surface when it is placed.

1 and 2, the needle part 20 of the drug administration device 10 is a structural part that constructs a drug introduction part by inserting and leaving a catheter 22 inside the body (subcutaneously) from the body surface. The needle part 20 is also assembled to an insertion device 50 before the catheter 22 is left in the patient, and the inner needle 52 of the insertion device 50 penetrates the catheter 22. The user of the drug administration device 10 punctures the body with the multi-needle 12 in which the catheter 22 and the inner needle 52 overlap, and further pulls out the inner needle 52 from the catheter 22 in the puncture state (detaches the insertion device 50 from the needle part 20), thereby leaving the catheter 22 in the patient. Note that, in order to facilitate understanding of the present invention, FIGS. 1 and 2 illustrate the needle part 20 and the insertion device 50 in a separated state.

Specifically, the needle portion 20 has a catheter 22 (outer needle), a hub 24 that holds the base end of the catheter 22 and to which the tube 40 is connected, and a needle portion side seal body 26 that attaches the hub 24 to the body surface.

The catheter 22 is a flexible tube having an internal lumen 22a through which a drug can flow, and protrudes downward from the lower surface (the surface facing the body surface) of the hub 24. The lumen 22a communicates with the distal end opening 22a1 of the catheter 22 and also communicates with a space 24a in the hub 24 at the proximal end side of the catheter 22. In the state of the multiple needle 12, the inner needle 52 is inserted into the lumen 22a, and the needle tip of the inner needle 52 protrudes from the distal end opening 22a1. The proximal end of the catheter 22 is fixed to the hub 24 by an appropriate fixing means such as adhesion, welding, or crimping. In this embodiment, the catheter 22 is fixed to the hub 24 by crimping a crimping pin (not shown).

The hub 24 is made of a resin material harder than the catheter 22, and has an internal space 24a through which the inner needle 52 can be inserted in the vertical direction and which communicates with the lumen 22a of the catheter 22 and the flow passage 40a of the tube 40. The hub 24 has an external shape that can engage with the lower part of the insertion device 50, and an inlet port 25 for connecting the tube 40 is provided on a specific side. In addition, a flat hub base plate 24b is formed on the lower part of the hub 24, and a needle side seal body 26 is affixed to the underside of this hub base plate 24b.

The needle-side seal body 26 is flexible and formed in a sheet shape that is wider in the planar direction than the hub substrate 24b. An upper adhesive surface (not shown) to which the hub substrate 24b is attached is provided in the approximate center of one surface (top surface) of the needle-side seal body 26.

A lower adhesive surface (not shown) that can be attached to the body surface is provided on the entire other surface (lower surface) of the needle side seal body 26, and the needle side mount 27 is attached to this lower adhesive surface before using the needle 20. This needle side mount 27 has an ear 27a that protrudes from the needle side seal body 26 and can be grasped by the user. A coating that makes it easy to peel off the adhesive surface is provided on the upper surface (opposing surface) of the needle side mount 27 to which the needle side seal body 26 is attached and the upper surface of the main body side mount 70 described below.

Furthermore, the hub 24 has a valve body 28 that closes the space 24a above the catheter 22. When the needle portion 20 and the insertion device 50 are assembled, the inner needle 52 is inserted through the valve body 28 into the lumen 22a of the catheter 22. In addition, on the upper surface of the hub 24, radially outward of the valve body 28, a pair of engagement holes 29 that engage with the insertion device 50 when the insertion device 50 is assembled are provided.

In an assembled state, the insertion device 50 is attached to the needle portion 20 so as to be movable upward, and inserts (punctures) the multiple needle 12 into the patient's body under the user's operation. The insertion device 50 has an inner needle 52, an inner needle holding portion 53 that holds the inner needle 52, and an operation housing 54 that surrounds the outside of the inner needle 52 and the inner needle holding portion 53. The operation housing 54 is formed to have an appropriate vertical length and thickness so that it is easy for the user to grasp and operate. The inner needle 52 is fixed to the inner needle holding portion 53, and extends along the axis of the cylindrical operation housing 54.

In addition, a pair of engagement pieces 56 extend downward between the inner needle 52 and the operation housing 54. The pair of engagement pieces 56 are respectively inserted into a pair of engagement holes 29 in the hub 24, and their lower ends protruding radially outward are caught in notches (not shown) in the hub 24, releasably engaging the needle 20 with the insertion device 50. The engagement force between the hub 24 and each engagement piece 56 is set to be weaker than the adhesive force when the needle side seal body 26 is attached to the body surface, and when the user pulls up the insertion device 50 with the needle side seal body 26 attached to the body surface, the engagement of each engagement piece 56 with the hub 24 is released.

The needle portion 20 and the insertion device 50 are not limited to the above configuration, and may have various configurations. For example, the insertion device 50 may be provided with a puncture mechanism that advances the needle portion 20 (catheter 22) and the inner needle 52 held by the operation housing 54 and punctures the body based on the operation of an operation means (button, etc.) not shown. The insertion device 50 may also be provided with an inner needle protection mechanism that prevents the inner needle 52 from accidentally puncturing the body by automatically pulling up the inner needle 52 relative to the catheter 22 after the multiple needle 12 is inserted into the body.

On the other hand, the device body 30 of the drug administration device 10 has the function of storing the drug and delivering the drug from the tip 31 at appropriate timing. This device body 30 has a case 32 in which a storage space is formed to store each component of the device body 30. Inside the case 32, there are provided a container 33 that stores the drug, a movement mechanism 35 that moves a gasket 34 inside the container 33, a control unit 36 that controls the operation of the movement mechanism 35, and a power supply unit (not shown) that can supply power to each component of the device body 30.

The case 32 has a generally rectangular shape that is large in the planar direction and low in the thickness direction. The four corners of the side periphery of the case 32 are rounded to form a smooth side wall 32a. The upper part of the case 32 (the surface exposed when placed) may be provided with a display unit (not shown) that allows the amount of stored medicine to be visually confirmed. The lower part of the case 32 is a flat lower wall portion 32b. In addition, a main body side connector 38 to which the tube 40 is connected is provided on one of the short sides of the side wall 32a of the case 32. In this embodiment, one of the short sides of the case 32 and the installation range of the main body side connector 38 correspond to the tip portion 31 of the device main body 30.

The container 33 is formed in a syringe shape, has a storage space 33a for storing an appropriate amount of medicine, and has an outflow port 39 at its tip for discharging the stored medicine. The outflow port 39 penetrates the side wall 32a at the tip side of the case 32 and is inserted into the cylindrical main body side connector 38. The outflow port 39 also has an outflow path (not shown) that communicates with the storage space 33a, and a valve body 39a is attached to this outflow path.

The main body side connector 38 connected to the outflow port 39 constitutes the tip 31 of the device main body 30 and protrudes slightly toward the tip from the case 32. The outer peripheral surface of the main body side connector 38 is provided with projections and recesses for connecting the tube side connector 42 described below, and is also provided with a pair of mounting holes 38a (see FIG. 3).

On the other hand, the gasket 34 liquid-tightly and slidably seals the base end of the drug filled in the container 33. A plunger 34a that advances the gasket 34 is attached to the base end of the gasket 34.

The moving mechanism 35 includes a movable body 35a that displaces the plunger 34a, a screw member 35b to which the movable body 35a is attached, a gear mechanism 35c that rotates the screw member 35b, and a motor 35d that applies a rotational driving force to the gear mechanism 35c. The movable body 35a and the screw member 35b constitute a ball screw mechanism that converts the rotation of the screw member 35b into a linear motion of the movable body 35a. The screw member 35b extends parallel to the axial direction (arrow A direction) of the plunger 34a, and both ends of the screw member 35b are supported by bearings not shown. The gear mechanism 35c transmits the rotational driving force of the motor 35d to the screw member 35b via multiple gears. The motor 35d rotates at an appropriate rotational speed by being supplied with power under the control of the control unit 36. The moving mechanism 35 that displaces the plunger 34a is not limited to the above configuration, and may be, for example, one that utilizes a magnetic force, a spring, a gas (fluid), or the like.

The control unit 36 is configured as a computer having a processor, memory, and input/output interface (not shown), and controls the operation of the motor 35d of the moving mechanism 35. The control unit 36 also has a communication module, and can set the drug administration timing, administration speed, administration amount, etc., using, for example, a controller (dedicated communication computer or general-purpose communication device (smartphone, etc.) (not shown) that can communicate with the control unit 36. The control unit 36 then measures the timing of the start of administration after placing the drug administration device 10 on the body surface, and rotates the motor 35d by an appropriate amount at the administration start timing to gradually move the movable body 35a toward the tip. As a result, the device main body 30 pushes the plunger 34a and the gasket 34 toward the tip side of the container 33, causing the drug in the container 33 to flow out from the outflow port 39.

The tube 40 of the drug administration device 10 is configured as a flexible tube that extends a predetermined length and has an internal flow passage 40a through which the drug can flow. One end of the tube 40 is fixed to the inlet port 25 of the needle portion 20 (hub 24) by an appropriate fixing means such as adhesive, welding, or crimping. A tube side connector 42 that can be detachably attached to the main body side connector 38 is fixed to the other end of the tube 40. The length of the tube 40 is not particularly limited, but is preferably set to a range of about 0.1 cm to 10 cm, for example.

The tube side connector 42 has a cylinder 43 that is fixed to the tube 40 and to which the main body side connector 38 can be attached, and a hollow needle 44 that protrudes along the central axis within the cylinder 43. The cylinder 43 is configured in a stepped shape with a fixed portion to which the tube 40 is fixed in advance and an inserted portion into which the main body side connector 38 is inserted. A pair of movable pieces 43a are provided in the inserted portion, and a connecting claw (not shown) is protruded from the inside of the protruding end of the movable piece 43a. When the tube side connector 42 and the main body side connector 38 are attached, the connecting claws engage with a pair of mounting holes 38a (see FIG. 3) of the main body side connector 38, thereby connecting the tube 40 and the device main body 30 to each other.

A needle hole (not shown) that communicates with the flow passage 40a of the tube 40 is provided inside the hollow needle 44. When the tube side connector 42 is connected to the main body side connector 38, the hollow needle 44 penetrates the valve body 39a of the outflow port 39, and communicates between the needle hole and the storage space 33a of the container 33.

The device body 30 of the drug injection device 10 according to this embodiment is attached to the patient's body surface by the body-side seal body 60. The body-side seal body 60 is formed in a rectangular shape with rounded corners in a plan view. More specifically, the body-side seal body 60 is similar to the lower wall portion 32b of the case 32, has a sheet shape that is wider in the planar direction than the lower wall portion 32b, and is flexible. A protrusion 61 that protrudes short in the proximal direction is formed at the base end of the body-side seal body 60.

In addition, one surface (top surface) of the body-side seal body 60 is provided with an upper adhesive surface 62 for attaching to the bottom wall portion 32b of the case 32. The shape of the upper adhesive surface 62 is formed to be substantially the same as or slightly smaller than the shape of the bottom wall portion 32b. The top surface of the body-side seal body 60, which is outside the upper adhesive surface 62, is a non-adhesive region 63 that does not have adhesiveness. The difference between the upper adhesive surface 62 and the non-adhesive region 63 allows the body-side seal body 60 to guide the attachment position of the case 32.

The short side on the tip side constituting the non-adhesive region 63 of the body-side seal body 60 protrudes by an amount less than the amount by which the body-side connector 38 protrudes from the case 32 when the device body 30 and the body-side seal body 60 are attached. The long sides on both sides in the width direction of the body-side seal body 60 and the short side on the base end side constituting the non-adhesive region 63 protrude by approximately the same amount as the short side on the tip side. The non-adhesive region 63 of the body-side seal body 60 can be easily deformed due to the flexibility of the body-side seal body 60 even when the device body 30 and the body-side seal body 60 are attached.

2, the other surface (lower surface) of the body-side seal body 60 is provided with a lower adhesive surface 64 for attaching the device body 30 to the body surface. The lower adhesive surface 64 is formed on the entire lower surface of the body-side seal body 60 (including the protruding portion 61). Therefore, when the body-side seal body 60 is attached to the body surface, the opposite surfaces of both the upper adhesive surface 62 on the upper surface and the non-adhesive region 63 are in close contact with the body surface.

The drug administration device 10 has a body-side mount 70 that covers the lower adhesive surface 64 of the body-side seal body 60 in an exposable manner before the device body 30 is attached to the body surface. As shown in FIG. 3, the body-side mount 70 is composed of multiple mounts (two in this embodiment). The first mount 72 covers the lower adhesive surface 64 on the tip side of the body-side seal body 60, while the second mount 80 covers the lower adhesive surface 64 on the base end side of the body-side seal body 60. In this embodiment, the second mount 80 extends so that its tip slightly overlaps the first mount 72 and is in contact with the base end of the first mount 72.

The first mount 72 extends in the width direction of the body-side seal body 60 (along the short side at the tip end), with both ends protruding outward beyond the long sides of the body-side seal body 60. In other words, the longitudinal direction of the first mount 72 coincides with the width directions of the device body 30 and the body-side seal body 60. Hereinafter, the portion of the first mount 72 that overlaps with the body-side seal body 60 is referred to as the first mount covering portion 74.

The first mount covering portion 74 of the first mount 72 extends linearly in the width direction along the short side on the tip side of the body-side seal body 60. The base end of the first mount covering portion 74 (first mount 72) is located slightly toward the tip side of the lower wall portion 32b of the case 32 (upper adhesive surface 62 of the body-side seal body 60). Meanwhile, the leading end of the first mount 72 coincides with the leading end of the body-side seal body 60. The base end of the first mount 72 may overlap slightly with the leading end side of the lower wall portion 32b of the case 32.

The first mount 72 is not particularly limited in its range as long as it covers the body-side seal body 60 at the tip 31 of the device body 30 (the position close to or overlapping the body-side connector 38), but it is preferable that it covers an area smaller than that of the second mount 80. For example, it is preferable that the first mount 72 covers an area of 1/3 or less of the lower adhesive surface 64 from the tip of the body-side seal body 60 toward the base end.

In the portion where the first mount 72 and the second mount 80 overlap each other, the first mount 72 is located lower and further away from the body-side seal body 60 than the second mount 80 (in other words, the first mount 72 sandwiches the second mount 80 between itself and the lower adhesive surface 64). Therefore, the portion of the first mount 72 that overlaps with the second mount 80 is not attached to the body-side seal body 60. This allows the body-side mount 70 to guide the user to first peel off the first mount 72 and then peel off the second mount 80. Note that the body-side mount 70 may be located such that the second mount 80 is located further away from the body-side seal body 60 than the first mount 72.

A pair of protruding portions protruding on both sides in the width direction of the first mount 72 constitute the portion that the user grips when peeling off the first mount 72 (hereinafter referred to as the first mount operating portion 76). The protruding length of each of the first mount operating portions 76 in the width direction is longer than the length of the short side direction of the first mount covering portion 74. In addition, the protruding ends of the pair of first mount operating portions 76 are formed in an arc shape that curves inward in the width direction from the base end toward the tip side. Note that the first mount operating portion 76 may protrude from only one of the two sides of the main body side seal body 60.

On the other hand, the second mount 80 is a mount that is peeled off to place the device body 30 on the body surface after the first mount 72 has been peeled off. The direction in which the second mount 80 extends (longitudinal direction) coincides with the longitudinal direction of the device body 30 (case 32) and is perpendicular to the longitudinal direction of the first mount 72. This second mount 80 has a second mount covering portion 82 that covers the body-side seal body 60, and a second mount operating portion 84 that is connected to the tip of the second mount covering portion 82 and folds back from the tip of the second mount covering portion 82 to extend in the proximal direction.

The second mount covering portion 82 generally conforms to the shape of the base end side (including the protruding portion 61) of the main body seal body 60, and covers a portion that overlaps the base end of the first mount 72 and the entire area of the lower adhesive surface 64 that is not covered by the first mount 72. The length of the portion of the tip of the second mount covering portion 82 that overlaps the first mount covering portion 74 may be set to approximately 1/5 or less of the length of the first mount 72 in the short direction.

The second mount covering portion 82 is configured to cover at least 2/3 of the range from the base end toward the tip end of the body-side seal body 60. By the second mount 80 covering at least 2/3 of the base end side of the body-side seal body 60, a large portion of the lower adhesive surface 64 is covered even when the body-side seal body 60 is temporarily attached to the body surface after the first mount 72 is peeled off, and contact by the user with the lower adhesive surface 64 can be effectively suppressed.

The second mount operating section 84 extends from the tip of the second mount covering section 82 beyond the base end of the device body 30. The tip of the second mount 80 has a strong crease 86 formed by folding the second mount operating section 84 against the second mount covering section 82. This crease 86 is covered by the base end of the first mount 72 when the medicine injection device 10 is in a pre-use state.

The second mount operation section 84 gradually narrows in width toward the base end, and has a protruding piece 84a that protrudes from the center of the width and toward the base end in the portion protruding from the base end of the device body 30. The protruding piece 84a extends further in the base end direction than the base end of the case 32 and the base end of the body-side seal body 60, and is therefore a portion that is grasped by the user when peeling off the second mount 80. In other words, the user can easily peel off the second mount 80 from the body-side seal body 60 by pulling the protruding piece 84a in the base end direction while grasping the protruding piece 84a.

The drug administration device 10 of this embodiment is basically configured as described above, and the method of placing this drug administration device 10 will be explained below.

When using the drug administration device 10, the needle portion 20, device body 30, and tube 40 are placed on the patient's body surface by the user, and after this placement, the drug is automatically administered to the patient under the control of the control unit 36. As shown in Figure 4, when the drug administration device 10 is placed, a needle portion placement step (step S1) in which the needle portion 20 is placed, a tube connection step (step S2) in which the tube 40 and device body 30 are connected, and a body placement step (step S3) in which the device body 30 is placed are performed in that order.

Specifically, the drug administration device 10 is provided to the user with the needle portion 20 and the insertion device 50 assembled, while the tube 40 connected to the needle portion 20 is separated from the device body 30. The needle portion side seal body 26 and the body side seal body 60 may be provided in a state where they are pre-attached to the needle portion 20 and the device body 30, or may be provided in a state where they are attached separately from the needle portion 20 and the device body 30, and the user may attach them before using the drug administration device 10.

In the needle placement step, the user first peels off the needle-side backing 27 from the needle-side seal body 26 attached to the needle 20. The user then grasps the insertion device 50 and positions the needle 20 directly above the desired position on the body surface, and lowers the insertion device 50 toward the body surface, thereby puncturing the multiple needles 12 protruding from the underside of the hub 24 into the body. As a result of this puncturing operation, the needle-side seal body 26 is attached to the body surface.

After puncture, the user releases the engagement between the needle portion 20 and the insertion device 50 by lifting the insertion device 50 relative to the needle portion 20, and removes the inner needle 52 from the catheter 22. At this time, the needle portion 20 attached to the needle side seal body 26 remains fixed to the body surface. In addition, when the inner needle 52, which had been inserted through the valve body 28 of the needle portion 20, is removed from the valve body 28, the valve body 28 self-closes to prevent blood leakage. This removal of the inner needle 52 from the needle portion 20 completes the placement of the needle portion 20.

Next, in the tube connection step, the user connects the tube side connector 42 of the tube 40 extending from the needle portion 20 to the main body side connector 38 of the device main body 30, as shown in FIG. 5. When connecting, the user inserts the main body side connector 38 into the cylindrical body 43 of the tube side connector 42, thereby piercing the hollow needle 44 of the tube side connector 42 into the valve body 39a. This allows the flow passage 40a of the tube 40 to communicate with the storage space 33a of the container 33 via the hollow needle 44. Then, when the tip of the tube side connector 42 reaches the back of the main body side connector 38, the connection claws of the pair of movable pieces 43a are caught in the pair of mounting holes 38a of the main body side connector 38, so that the tube side connector 42 and the main body side connector 38 engage with each other in a liquid-tight manner.

Then, in the final main body placement step, the user first performs a first mount peeling step of peeling off the first mount 72 from the device main body 30, as shown in Figure 6. In the first mount peeling step, the user pinches one of a pair of first mount operating parts 76 protruding from the main body side seal body 60 and pulls the first mount 72 along the width direction of the main body side seal body 60. This allows the first mount 72 to be easily peeled off from the main body side seal body 60, and the tip side of the main body side seal body 60 is exposed.

After the first backing peeling step, the user temporarily attaches the tip side of the exposed body-side seal body 60 to the body surface so that the connected tube-side connector 42 and body-side connector 38 are spaced at an appropriate distance, thereby positioning the tip side of the device body 30 (see also FIG. 7). That is, the user can guide the connected tube-side connector 42 and body-side connector 38 to a position on the body surface near the placement site of the needle portion 20, and temporarily fix the body-side connector 38 with the tip side of the body-side seal body 60. Thus, the user can maintain a stable connection between the device body 30 and the tube 40.

Then, with the device body 30 temporarily fixed, the user performs a second mount peeling step of peeling off the second mount 80 from the body-side seal body 60 as shown in FIG. 7. In the second mount peeling step, with the tip side of the body-side seal body 60 attached to the body surface, the user pinches the protruding piece 84a protruding from the base end side of the device body 30 and pulls the second mount operation part 84 in the base end direction. As a result, the second mount covering part 82 of the body-side seal body 60 peels off from the tip in the base end direction while maintaining the attachment of the tip side that has already been attached. When the lower adhesive surface 64 of the body-side seal body 60 is exposed with the peeling off of the second mount 80, it is immediately attached to the nearby opposing body surface. When the user pulls off the second mount operation part 84, the entire exposed lower adhesive surface 64 is attached to the body surface.

That is, the user can place the device body 30 in the vicinity of the needle portion 20 without shifting the position of the device body 30 by simply peeling off the second backing 80 from the device body 30 and the body-side seal body 60 that have been positioned previously. This allows the drug administration device 10 to place the device body 30 in a good position without pulling on the tube 40 when setting the device body 30.

When the device body 30 is in place, the body-side seal body 60 has a non-adhesive area 63 on the outside of the case 32, and the lower adhesive surface 64 on the back of this non-adhesive area 63 is attached to the body surface. As a result, even if an external force is applied, such as pulling on the case 32, the body-side seal body 60 in the non-adhesive area 63 continues to be attached to the body surface while flexing, and the body-side seal body 60 is prevented from immediately peeling off.

The present invention is not limited to the above embodiment, and various modifications are possible in accordance with the gist of the invention. For example, the main body side mount 70 may be composed of not only two sheets, the first mount 72 and the second mount 80, but also three or more sheets. As an example, the first mount 72 may be configured to cover the tip side of the main body side seal body 60 by dividing it into two mounts at the center in the longitudinal direction. In addition, the main body side mount 70 may be configured such that the first mount 72 and the second mount 80 do not have a mutually overlapping portion, and the tip of the second mount 80 is arranged in a position adjacent to the first mount 72 (without contacting it).

Furthermore, in this embodiment, the first mount operating section 76 is protruded outward in the width direction of the body-side seal body 60, so that the peeling direction of the first mount 72 is the width direction perpendicular to the peeling direction of the second mount 80. However, the peeling direction of the first mount 72 may be toward the tip or base end of the body-side seal body 60, in which case the first mount operating section 76 may be configured to be continuous with the tip edge or base edge of the first mount covering section 74.

The method of placement of the drug administration device 10 is not limited to the above procedure. For example, the user may perform the first backing peeling step before connecting the tube side connector 42 of the tube 40 and the body side connector 38 of the device body 30 in the tube connection step. This allows the tip side of the device body 30 to be temporarily attached to the body surface via the body side seal body 60, and the user can easily connect the tube side connector 42 and the body side connector 38 in a temporarily attached state. This procedure reduces inconveniences such as pulling the needle portion 20 that was previously placed through the tube 40 when connecting the connectors.

8, the second mount 80A may be formed such that the second mount operating section 84 has the same shape as the second mount covering section 82 in a plan view. If the second mount covering section 82 and the second mount operating section 84 have the same shape, the second mount 80A can be easily manufactured by punching out the second mount covering section 82 and the second mount operating section 84 together in a state in which the second mount operating section 84 is folded back relative to the second mount covering section 82.

The technical ideas and effects that can be understood from the above embodiments are described below.

One aspect of the present invention is a drug administration device 10 comprising a needle portion 20 that is inserted and left in place in a living body, a device body 30 that is provided separately from the needle portion 20 and capable of delivering a drug from a tip portion 31, and a tube 40 that allows drug to flow between the needle portion 20 and the tip portion 31 of the device body 30, in which the device body 30 comprises a seal body (body-side seal body 60) having an adhesive surface (lower adhesive surface 64) that is attached to the body surface of the living body, and a mount (body-side mount 70) that covers the adhesive surface so that it can be exposed before use, the mount including a first mount 72 that covers the tip side of the seal body, and a second mount 80, 80A that covers at least the base end side of the seal body, the second mount 80, 80A having a covering portion (second mount covering portion 82) that covers the adhesive surface, and an operating portion (second mount operating portion 84) that is connected to the tip of the covering portion and folds back from the tip of the covering portion to extend beyond the base end of the device body 30.

In the above-mentioned drug administration device 10, when connecting the tube 40 to the tip 31 of the device body 30, the first mount 72 can be peeled off to leave the tip side of the seal body (main body side seal body 60) temporarily attached to the body surface, making it possible to easily connect the tube 40 and the device body 30. In addition, when peeling off the second mount 80, 80A after connecting the tube 40 to the device body 30, the second mount 80, 80A can be easily detached by pulling the operation part (second mount operation part 84) extending from the base end of the device body 30. At this time, since the tip side of the seal body of the device body 30 is positioned, external force is suppressed from being applied to the needle part 20 after placement. That is, even in the drug administration device 10 in which the needle part 20 and the device body 30 are connected by the tube 40, the device body 30 can be well attached to the body surface of a living body by the simple configuration of having the first mount 72 and the second mount 80, 80A.

The first mount 72 covers less than 1/3 of the seal body (main body seal body 60) from its leading edge toward its base end, while the second mount 80, 80A covers more than 2/3 of the seal body from its very base end toward its tip end. This allows the user to easily position the tip side of the seal body exposed by peeling off the first mount 72 at a desired position on the body surface and temporarily attach it. The user can then peel off the second mount 80 to firmly attach the entire seal body to the body surface.

In addition, the tip of the second mount 80, 80A is positioned at a contact position or a position close to the base end of the first mount 72. This allows the main body side mount 70 to provide excellent protection for the entire lower adhesive surface 64 of the main body side seal body 60.

In addition, the base end of the first mount 72 and the tips of the second mounts 80, 80A overlap each other, and in the overlapping portion, the first mount 72 is located farther from the seal body (main body side seal body 60) than the second mounts 80, 80A. This allows the drug administration device 10 to guide the user in the peeling order, such as peeling off the first mount 72 first, and then peeling off the second mounts 80, 80A.

The device main body 30 has a case 32 having a storage space 33a for storing the drug, and a main body connector 38 that protrudes from the tip of the case 32 and is connected to a tube 40, and the seal body (main body seal body 60) is attached to the case 32 and has a portion that extends outside the case 32 in a plan view and is attached to the body surface. As a result, the portion of the seal body that extends outside the case 32 is attached to the body surface, so that even if the case 32 is pulled, for example, the extending portion deforms and the seal body can continue to be attached to the body surface satisfactorily.

One end of the tube 40 is fixed to the needle portion 20, while the other end of the tube 40 is removably attached to the tip portion 31 of the device body 30. This allows the drug administration device 10 to easily attach the tube 40 connected to the needle portion 20 to the device body 30 when the device body 30 is in a temporary attachment state.

In addition, the longitudinal direction of the first mount 72 is perpendicular to the longitudinal direction of the second mounts 80, 80A. This allows the user to peel off the first mount 72 in a direction different from that of the second mounts 80, 80A (the longitudinal direction of the first mount 72), making it easy to peel off the first mount 72.

The first mount 72 also has a first mount covering portion 74 that covers the seal body (main body-side seal body 60) and a first mount operating portion 76 that protrudes outward from at least one of both sides of the seal body and constitutes a portion that is gripped by the user. This allows the user to peel off the first mount 72 by simply gripping the first mount operating portion 76 that protrudes from the seal body.

In addition, the second mount operating part 84 is formed to be narrower than the width of the base end of the device body 30, and extends from the center in the width direction of the base end of the device body 30. This allows the user to pull the second mount operating part 84 in the base end direction, thereby suppressing kinking of the body-side seal body 60 and stably peeling off the second mounts 80, 80A.

In addition, the second mount operating portion 84 protrudes in the base end direction beyond the base end of the second mount covering portion 82. This allows the user to simply pinch the second mount operating portion 84 protruding from the second mount covering portion 82 to peel off the second mounts 80, 80A.

In addition, the second mount operation section 84 is formed in the same shape as the second mount covering section 82 in a plan view. This allows the second mounts 80, 80A to be easily formed by punching out the second mount covering section 82 and the second mount operation section 84 in the manufacture of the second mounts 80, 80A.

Claims (9)

A drug administration device comprising: a needle portion that is inserted into a living body and left therein; a device body that is provided separately from the needle portion and is capable of delivering a drug from a tip portion; and a tube that allows the drug to flow between the needle portion and the tip portion of the device body,
the device body includes a seal body having an adhesive surface to be attached to a body surface of the living body, and a mount that covers the adhesive surface before use so as to be exposed;
The mount includes a first mount covering a tip end side of the seal body,
and a second backing covering at least the base end side of the seal body,
the second mount has a covering portion that covers the adhesive surface, and an operation portion that is connected to a tip of the covering portion and is folded back from the tip of the covering portion to extend beyond a base end of the device body ,
the first mount covers the seal body at the tip of the device body in an area smaller than that of the second mount,
the second mount covers the seal body on a side closer to a base end of the device body than the first mount,
a base end of the first mount and a tip end of the second mount have overlapping portions,
In the overlapping portion, the first backing is located farther from the seal body than the second backing.
Drug administration device. 2. The drug administration device according to claim 1,
The first mount covers an area of 1/3 or less from the leading end of the seal body toward the base end,
The medicine injection device, wherein the second mount covers at least 2/3 of the range of the seal body from the most proximal end toward the distal end. 3. The drug administration device according to claim 1,
the device body includes a case having a storage space for storing the drug, and a body-side connector protruding from a tip of the case and to which the tube is connected;
The seal body is attached to the case and has a portion that extends outside the case in a plan view and is attached to the body surface. The drug administration device according to any one of claims 1 to 3 ,
A drug injection device, wherein one end of the tube is fixed to the needle portion, while the other end of the tube is detachably attached to the tip portion of the device body. The drug administration device according to any one of claims 1 to 4 ,
A medicine injection device, wherein a longitudinal direction of the first mount is perpendicular to a longitudinal direction of the second mount. 6. The drug administration device according to claim 5 ,
The first mount includes a first mount covering portion that covers the seal body,
a first mount operation portion that protrudes outward from at least one of both sides of the seal body and constitutes a portion that is gripped by a user. The drug administration device according to any one of claims 1 to 6 ,
A medicine injection device, wherein the operation section is formed to be narrower than a width of a base end of the device body and extends from a widthwise center of the base end of the device body. 8. The drug administration device according to claim 7 ,
The operation portion protrudes in a proximal direction beyond a proximal end of the covering portion. 9. The drug administration device according to claim 8 ,
The medicine injection device, wherein the operation portion is formed in the same shape as the covering portion in a plan view.